Northwest Bio says updated IPD analyses show DCVax-L extends glioblastoma survival more than prior Phase III readout

NORTHWEST BIOTHERAPEUTICS INC

NORTHWEST BIOTHERAPEUTICS INC

NWBO

0.00
  • Northwest Biotherapeutics presented updated Phase III DCVax-L survival analyses in newly diagnosed glioblastoma, suggesting the original benefit estimate was understated.
  • Independent IPD-based propensity score matching showed median survival gains of 3.4 to 6.3 months vs controls; hazard ratios 0.69 to 0.77; p values 0.004 to 0.027.
  • The original cohort-level analysis reported a 2.8-month median survival advantage.
  • Inverse probability weighting produced similar results, showing a 3.4 to 4.3-month median survival advantage.
  • Sensitivity tests using E-values and Rosenbaum’s Gamma indicated the effect was unlikely driven by hidden imbalances between treated patients and controls.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Northwest Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607081424PR_NEWS_USPR_____SF00707) on July 08, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.